Cargando…

Elevation in Inflammatory Serum Biomarkers Predicts Response to Trastuzumab-Containing Therapy

Approximately half of all HER2/neu-overexpressing breast cancer patients do not respond to trastuzumab-containing therapy. Therefore, there remains an urgent and unmet clinical need for the development of predictive biomarkers for trastuzumab response. Recently, several lines of evidence have demons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alkhateeb, Ahmed A., Leitzel, Kim, Ali, Suhail M., Campbell-Baird, Cynthia, Evans, Matthew, Fuchs, Eva-Maria, Köstler, Wolfgang J., Lipton, Allan, Connor, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530544/ https://www.ncbi.nlm.nih.gov/pubmed/23300545 http://dx.doi.org/10.1371/journal.pone.0051379

Ejemplares similares

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
por: Lobo-Martins, Soraia, et al.
Publicado: (2020)

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
por: Kopreski, M. S., et al.
Publicado: (1997)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
por: Díaz‐Antón, Belén, et al.
Publicado: (2022)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer
por: Willumsen, Nicholas, et al.
Publicado: (2019)

Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics
por: George, Bijesh, et al.
Publicado: (2021)

Nitromethane-containing fuel toxicity causing falsely elevated serum creatinine
por: Patel, Satish, et al.
Publicado: (2008)

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
por: Perrier, Alexandre, et al.
Publicado: (2020)

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations
por: Koay, Debbie C, et al.
Publicado: (2010)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
por: Zhou, Qiong, et al.
Publicado: (2020)

Elevated serum globulin fraction as a biomarker of multiyear disease severity in inflammatory bowel disease
por: Hashash, Jana G., et al.
Publicado: (2022)

Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer
por: Kamai, Takao, et al.
Publicado: (2018)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
por: Castro-Guijarro, Ana Carla, et al.
Publicado: (2023)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Elevated Serum Purine Levels in Schizophrenia: A Reverse Translational Study to Identify Novel Inflammatory Biomarkers
por: Kristóf, Zsüliet, et al.
Publicado: (2022)

Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles
por: Barth, Christina, et al.
Publicado: (2021)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine
por: Singhal, Rohit, et al.
Publicado: (2014)

Elevated serum trimethylamine oxide levels as potential biomarker for diabetic kidney disease
por: Huang, Yinqiong, et al.
Publicado: (2023)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
por: Hudelist, G, et al.
Publicado: (2003)

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients
por: Koh, Jiwon, et al.
Publicado: (2019)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
por: Engebraaten, Olav, et al.
Publicado: (2021)

Impulsive Fire Disturbance in a Savanna Model: Tree–Grass Coexistence States, Multiple Stable System States, and Resilience
por: Hoyer-Leitzel, Alanna, et al.
Publicado: (2021)

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types
por: Willumsen, Nicholas, et al.
Publicado: (2022)

Serum Levels of Joining Chain-Containing IgA1 Are Not Elevated in Patients with IgA Nephropathy
por: Li, Guanhong, et al.
Publicado: (2019)

Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels
por: Santotoribio, Jose D., et al.
Publicado: (2019)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Prolonged Serum Alanine Aminotransferase Elevation Associated with Isotretinoin Administration
por: Nazarian, Roya S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1uvnq51igi6rrbra18bjjoppbs